Aura Biosciences to Present at the 15th Annual Needham Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that Elisabet de los Pinos, founder and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference in New York, N.Y.

The presentation will take place on Tuesday, April 12, 2016, at 2:40 p.m. EDT.

About Aura Biosciences

Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration. For more information, visit www.aurabiosciences.com.

Media Contact

Ann Stanesa, 617-230-0347
Ten Bridge Communications
ann@tenbridgecommunications.com

Investor Contact

Mike Wyzga, Chief Financial Officer
Aura Biosciences
mswyzga@verizon.net

Back to News & Publications

Written by:

Comment on this blog post by clicking the Post Comment button below, clicking the icon, and entering your name and email address. Any comments submitted without both a name and email address will not be approved to post publicly. For more information, read Aura’s blog guidelines here.